Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Biallelic Deletion of TNFRSF17 Associated With Resistance to BCMA-Targeting Therapies In Myeloma
Identifying BCMA expression, copy number variation, and point mutations can have important therapeutic implications for patients receiving BCMA-targeting CAR T-cell therapy or T-cell engagers for multiple myeloma.
The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone (RVd) induction and consolidation treatment and lenalidomide maintenance therapy (D-RVd/D-R) resulted in high minimal residual disease rates and prolonged progression-free survival in patients with transplant-eligible, newly diagnosed multiple myeloma.
Busulfan/Melphalan Prior to ASCT Fails to Elicit PFS Benefit in Newly Diagnosed Myeloma
August 28th 2022High-dose busulfan plus melphalan failed to generate a progression-free survival benefit vs melphalan for autologous stem cell transplant conditioning in patients with newly diagnosed multiple myeloma after induction therapy.
Multiple Myeloma Armamentarium Is Set to Explode as Novel Agents Show Encouraging Early Data
Agents with novel mechanisms, including bispecific antibodies, immunomodulatory drugs, and antibody-drug conjugates, are displaying promising results in patients with relapsed or refractory multiple myeloma.
Isatuximab Plus Carfilzomib/Dexamethasone Maintains Survival Benefit in Relapsed Multiple Myeloma
August 26th 2022The combination of Isatuximab plus carfilzomib and dexamethasone continued to demonstrate a progression-free survival benefit vs carfilzomib and dexamethasone alone in relapsed multiple myeloma.
The triplet regimen of lenalidomide, bortezomib, and dexamethasone plus autologous stem cell transplantation and lenalidomide maintenance therapy significantly improved progression-free survival compared with RVd alone in patients with newly diagnosed multiple myeloma, with notable benefit observed in those with high-risk cytogenetics.
Long-Term Treatment with Daratumumab Plus Lenalidomide/Dexamethasone Boosts OS Benefits in Myeloma
Treatment with daratumumab plus lenalidomide and dexamethasone for at least 18 months led to deep clinical responses in patients with treatment-naïve multiple myeloma who were transplant ineligible.
Isatuximab Plus Pomalidomide and Dexamethasone Shows Meaningful PFS Benefit in Multiple Myeloma
Isatuximab plus pomalidomide and dexamethasone elicited favorable progression-free survival and proved tolerable in pretreated patients with relapsed/refractory multiple myeloma.
Targeted Therapies Continue to Shift Treatment Armamentarium in Multiple Myeloma
August 26th 2022Patient outcomes across the multiple myeloma landscape have vastly improved with the approval of multiple agents in the treatment armementarium, such as belantamab mafodotin-blmf, selinexor, and ciltacabtagene autoleucel.
